These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 731264)

  • 1. Regional cerebral blood flow in parkinsonism. Measurement before and after levodopa.
    Melamed E; Lavy S; Cooper G; Bentin S
    J Neurol Sci; 1978 Oct; 38(3):391-7. PubMed ID: 731264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effects of dopamine on regional cerebral blood flow in patients with Parkinson's disease before and after L-dopa--measurement by Xe-enhanced CT].
    Aiba I; Indo T; Takahashi A
    Rinsho Shinkeigaku; 1994 Nov; 34(11):1099-104. PubMed ID: 7729088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa-induced regional cerebral blood flow changes in normal volunteers and patients with Parkinson's disease. Lack of correlation with clinical or neuropsychological improvements.
    Montastruc JL; Celsis P; Agniel A; Demonet JF; Doyon B; Puel M; Marc-Vergnes JP; Rascol A
    Mov Disord; 1987; 2(4):279-89. PubMed ID: 3509776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional cerebral blood flow in patients with Parkinson's disease under chronic levodopa therapy: measurements during "on" and "off" response fluctuations.
    Melamed E; Globus M; Mildworf B
    J Neurol Neurosurg Psychiatry; 1986 Nov; 49(11):1301-4. PubMed ID: 3025375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional cerebral blood flow in hemiparkinsonian patients. Emission computerized tomography of inhaled 133Xenon before and after levodopa.
    Henriksen L; Boas J
    Acta Neurol Scand; 1985 Apr; 71(4):257-66. PubMed ID: 3873779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of intravenous L-dopa on P300 and regional cerebral blood flow in parkinsonism.
    Oishi M; Mochizuki Y; Hara M; Du CM; Takasu T
    Int J Neurosci; 1996 Mar; 85(1-2):147-54. PubMed ID: 8727690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of L-DOPA on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease.
    Leenders KL; Wolfson L; Gibbs JM; Wise RJ; Causon R; Jones T; Legg NJ
    Brain; 1985 Mar; 108 ( Pt 1)():171-91. PubMed ID: 3978397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa-induced local cerebral blood flow changes in Parkinson's disease and related disorders.
    Kobari M; Fukuuchi Y; Shinohara T; Obara K; Nogawa S
    J Neurol Sci; 1995 Feb; 128(2):212-8. PubMed ID: 7738597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].
    Londoõ R
    Neurol Neurocir Psiquiatr; 1976; 17(4):293-300. PubMed ID: 1018729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Characteristics of regional cerebral circulation in parkinsonism patients according the 133Xe clearance findings].
    Man'kovskii NB; Vanishtok AB; Lizogub VG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1977; 77(1):51-5. PubMed ID: 842227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional cerebral blood flow in patients with Parkinson's disease.
    Lavy S; Melamed E; Cooper G; Bentin S; Rinot Y
    Arch Neurol; 1979 Jun; 36(6):344-8. PubMed ID: 454231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease.
    Lieberman A; Goodgold A; Jonas S; Leibowitz M
    Neurology; 1975 Oct; 25(10):911-6. PubMed ID: 1101099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
    Mizuno Y; Yoshida M; Obayashi T; Ueki A
    Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
    [No Abstract]   [Full Text] [Related]  

  • 14. L-dopa-carbidopa: combined therapy for the treatment of Parkinson's disease.
    Celesia GG; Wanamaker WM
    Dis Nerv Syst; 1976 Mar; 37(3):123-5. PubMed ID: 1253661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopa-induced blood flow responses in nonhuman primates.
    Hershey T; Black KJ; Carl JL; Perlmutter JS
    Exp Neurol; 2000 Dec; 166(2):342-9. PubMed ID: 11085899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of Parkinson's syndrome with a combination of levodopa and carbidopa].
    Lombardo L; De la Garza R
    Arch Invest Med (Mex); 1977; 8(2):123-8. PubMed ID: 907417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local cerebral blood flow and its response to intravenous levodopa in progressive supranuclear palsy. Comparison with Parkinson's disease.
    Kobari M; Fukuuchi Y; Shinohara T; Nogawa S; Takahashi K
    Arch Neurol; 1992 Jul; 49(7):725-30. PubMed ID: 1497499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of levodopa with carbidopa or benserazide in parkinsonism.
    Greenacre JK; Coxon A; Petrie A; Reid JL
    Lancet; 1976 Aug; 2(7982):381-4. PubMed ID: 73849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
    Pahwa R; Koller WC
    Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.